Bladder cancer is one of the most common urological cancers, with nonmuscle invasive forms accounting for a significant portion of new diagnoses. In September, UC Davis Comprehensive Cancer Center announced it has become the first in the region to offer a pioneering clinical trial targeting intermediate-risk nonmuscle invasive bladder cancer (IR-NMIBC).

The study, known as PIVOT-006, is a phase 3 randomized controlled trial that compares the experimental drug cretostimogene against observation, aiming to improve outcomes and preserve the bladder in affected patients.

Patients with IR-NMIBC normally undergo a surgical procedure known as transurethral resection of the bladder tumor to remove visible cancerous tissue. Despite this intervention, many who undergo it face cancer recurrence, wh

See Full Page